Researchers investigated how sodium–glucose cotransporter 2 inhibitors (SGLT2is) impact hospitalization for heart failure (HHF) and cardiac structure/function, by analyzing relevant randomized controlled trials (RCTs). They also intended to explore RCT-derived evidence for SGLT2i efficacy mechanisms in heart failure. They searched Medline and Embase. Findings revealed that a decrease in HHF was conferred by SGLT2is, irrespective of type-2 diabetes mellitus status, and a possible contributor to this efficacy was reversal of adverse left ventricular remodelling. Hypothesis-driven mechanistic trials remain sparse.
Read the full article on ESC Heart Failure.